PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert V...(EXEL.com target _new http://www.PAREXEL...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
EXEL.com" target="_new">http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future
results and events. For this purpose, any statements contained herein that
are not statements of historical fact may be deemed forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "intends," "appears," "estimates,"
"projects," "targets," and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements in this
release involve a number of risks and uncertainties. The Company's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Important factors
that might cause such a difference include, but are not limited to, risks
associated with: actual operating performance; actual expense savings and
other operating improvements resulting from recent restructurings; the
loss, modification, or delay of contracts which would, among other things,
adversely impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the Company's
ability to win new business, manage growth and costs, and attract and
retain employees; the Company's ability to complete additional acquisitions
and to integrate newly acquired businesses or enter into new lines of
business; the impact on the Company's business of government regulation of
the drug, medical device and biotechnology industry; consolidation within
the pharmaceutical industry and competition within the biopharmaceutical
services industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform; and the
effects of exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Compan
'/>"/>
| SOURCE PAREXEL International Corporation Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |